Lineage Cell Therapeutics, Inc.
LCTX · FY2025 · Fiscal year ended Dec 31, 2025 · 10-K filed Mar 2026
Open the dashboardInfographicSummary
FY2025 key figures
| $ | FY2025 | FY2024 | Change |
|---|---|---|---|
| Revenue | $14.6M | $9.50M | +53.3% |
| Operating income | −$36.6M | −$21.5M | −70.5% |
| Net income | −$63.5M | −$18.6M | −241% |
Latest quarter: Q3 2026
Form 10-Q · Three months ended Sep 30, 2026 · filed Nov 12, 2026
| $ | Q3 2026 | Year earlier | Change |
|---|---|---|---|
| Revenue | $1.40M | $3.70M | −62.2% |
| Operating income | −$7.30M | −$3.80M | −92.1% |
| Net income | $4.20M | −$29.8M |
Q3 2026 dashboardQ3 2026 infographic
Questions
- What was Lineage Cell's revenue in FY2025?
- $14.6M in FY2025 (Fiscal year ended Dec 31, 2025), +53.3% vs $9.50M a year earlier, per its 10-K filed Mar 2026.
- Was Lineage Cell profitable in FY2025?
- No: net income was −$63.5M and operating income −$36.6M in FY2025.
- What was Lineage Cell's revenue in Q3 2026?
- $1.40M (−62.2% vs a year earlier), per its Form 10-Q filed Nov 12, 2026.